Literature DB >> 26468153

Towards an Earlier and Timely Diagnosis of Type 1 Diabetes: Is it Time to Change Criteria to Define Disease Onset?

Manuela Battaglia1, Laura Nigi2,3, Francesco Dotta2,3.   

Abstract

Type 1 diabetes (T1D) is the immune-mediated form of diabetes requiring insulin treatment and affecting both children and adults. The incidence of T1D is increasing dramatically and has doubled in the past 2 decades. In the recent years, significant knowledge on the disease natural history has been gained and, nowadays, diabetes-related autoantibodies make T1D a predictable disease. Despite this great advance in the field of T1D, we still use diagnostic criteria defined by the American Diabetes Association (ADA) in 1997. In other autoimmune endocrine disorders (e.g., Hashimoto's thyroiditis and Addison's disease), that share several features with T1D, diagnosis is made early in the presence of circulating autoantibodies together with subclinical thyroid/adrenal functional impairment and treatments are often provided in the absence of a frank clinical glandular insufficiency. With this review, we propose to anticipate diagnosis also in T1D at the stage in which subjects have circulating multiple islet autoantibodies, are dysglycemic but are still insulin independent. We believe that anticipating T1D diagnosis can lead to better disease management and prevention of secondary complications but can also provide the possibility to perform earlier and likely more effective interventions for a disease that to date has proven controllable but still incurable.

Entities:  

Keywords:  Diagnosis; Glycemia; Islet autoantibodies; Type 1 diabetes

Mesh:

Substances:

Year:  2015        PMID: 26468153     DOI: 10.1007/s11892-015-0690-6

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  21 in total

1.  Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement.

Authors:  Jacqueline Jonklaas; Antonio C Bianco; Andrew J Bauer; Kenneth D Burman; Anne R Cappola; Francesco S Celi; David S Cooper; Brian W Kim; Robin P Peeters; M Sara Rosenthal; Anna M Sawka
Journal:  Thyroid       Date:  2014-12       Impact factor: 6.568

Review 2.  Why treat early multiple sclerosis patients?

Authors:  G Comi
Journal:  Curr Opin Neurol       Date:  2000-06       Impact factor: 5.710

Review 3.  Disease modifying therapies in type 1 diabetes: Where have we been, and where are we going?

Authors:  Sandra Lord; Carla J Greenbaum
Journal:  Pharmacol Res       Date:  2015-03-11       Impact factor: 7.658

4.  Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children.

Authors:  Anette G Ziegler; Marian Rewers; Olli Simell; Tuula Simell; Johanna Lempainen; Andrea Steck; Christiane Winkler; Jorma Ilonen; Riitta Veijola; Mikael Knip; Ezio Bonifacio; George S Eisenbarth
Journal:  JAMA       Date:  2013-06-19       Impact factor: 56.272

Review 5.  The metabolic progression to type 1 diabetes as indicated by serial oral glucose tolerance testing in the Diabetes Prevention Trial-type 1.

Authors:  Jay M Sosenko; Jay S Skyler; Kevan C Herold; Jerry P Palmer
Journal:  Diabetes       Date:  2012-06       Impact factor: 9.461

6.  Molecular signatures differentiate immune states in type 1 diabetic families.

Authors:  Yi-Guang Chen; Susanne M Cabrera; Shuang Jia; Mary L Kaldunski; Joanna Kramer; Sami Cheong; Rhonda Geoffrey; Mark F Roethle; Jeffrey E Woodliff; Carla J Greenbaum; Xujing Wang; Martin J Hessner
Journal:  Diabetes       Date:  2014-04-23       Impact factor: 9.461

7.  Acceleration of the loss of the first-phase insulin response during the progression to type 1 diabetes in diabetes prevention trial-type 1 participants.

Authors:  Jay M Sosenko; Jay S Skyler; Craig A Beam; Jeffrey P Krischer; Carla J Greenbaum; Jeffrey Mahon; Lisa E Rafkin; Della Matheson; Kevan C Herold; Jerry P Palmer
Journal:  Diabetes       Date:  2013-07-17       Impact factor: 9.461

8.  Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes.

Authors:  Gayatri Sarkar; May Alattar; Rebecca J Brown; Michael J Quon; David M Harlan; Kristina I Rother
Journal:  Diabetes Care       Date:  2013-11-05       Impact factor: 19.112

Review 9.  Therapy of endocrine disease: Perspectives on the management of adrenal insufficiency: clinical insights from across Europe.

Authors:  Ashley Grossman; Gudmundur Johannsson; Marcus Quinkler; Pierre Zelissen
Journal:  Eur J Endocrinol       Date:  2013-10-21       Impact factor: 6.664

10.  Blood and islet phenotypes indicate immunological heterogeneity in type 1 diabetes.

Authors:  Sefina Arif; Pia Leete; Vy Nguyen; Katherine Marks; Nurhanani Mohamed Nor; Megan Estorninho; Deborah Kronenberg-Versteeg; Polly J Bingley; John A Todd; Catherine Guy; David B Dunger; Jake Powrie; Abby Willcox; Alan K Foulis; Sarah J Richardson; Emanuele de Rinaldis; Noel G Morgan; Anna Lorenc; Mark Peakman
Journal:  Diabetes       Date:  2014-06-17       Impact factor: 9.461

View more
  2 in total

Review 1.  Circulating microRNAs and diabetes mellitus: a novel tool for disease prediction, diagnosis, and staging?

Authors:  G Sebastiani; L Nigi; G E Grieco; F Mancarella; G Ventriglia; F Dotta
Journal:  J Endocrinol Invest       Date:  2017-02-17       Impact factor: 4.256

Review 2.  Overlooked Mechanisms in Type 1 Diabetes Etiology: How Unique Costimulatory Molecules Contribute to Diabetogenesis.

Authors:  David H Wagner
Journal:  Front Endocrinol (Lausanne)       Date:  2017-08-23       Impact factor: 5.555

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.